Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

Takehiko Mori, Rie Yamazaki, Yoshinobu Aisa, Tomonori Nakazato, Masumi Kudo, Tomoko Yashima, Sakiko Kondo, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis. The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with fludarabine alone or with fludarabine and additional radiation were enrolled in the study. The severity of stomatitis was graded according to the National Cancer Institute - Common Toxicity Criteria. Patients were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). Patients who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8%) of 17 patients receiving 60-min oral cryotherapy and 2 (11.1%) of 18 patients receiving 120-min oral cryotherapy developed grade 2 or 3 stomatitis, respectively. The difference between groups was not statistically significant (P=0.677). The incidence of unpleasant symptoms such as chills and nausea during oral cryotherapy decreased significantly with 60-min oral cryotherapy, as compared with that associated with 120-min oral cryotherapy (P<0.01). These results suggest that 60-min oral cryotherapy is as effective as 120-min oral cryotherapy at preventing high-dose melphalan-induced stomatitis, and shorter treatment might have contributed to relieve patient discomfort during oral cryotherapy.

Original languageEnglish
Pages (from-to)392-395
Number of pages4
JournalSupportive Care in Cancer
Volume14
Issue number4
DOIs
Publication statusPublished - 2006 Apr

Fingerprint

Stomatitis
Cryotherapy
Melphalan
Hematopoietic Stem Cells
Transplants
Transplant Recipients
Chills
National Cancer Institute (U.S.)
Nausea

Keywords

  • Hematopoietic stem cell transplantation
  • High-dose melphalan
  • Oral cryotherapy
  • Stomatitis

ASJC Scopus subject areas

  • Oncology
  • Nursing(all)

Cite this

Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. / Mori, Takehiko; Yamazaki, Rie; Aisa, Yoshinobu; Nakazato, Tomonori; Kudo, Masumi; Yashima, Tomoko; Kondo, Sakiko; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Supportive Care in Cancer, Vol. 14, No. 4, 04.2006, p. 392-395.

Research output: Contribution to journalArticle

Mori, Takehiko ; Yamazaki, Rie ; Aisa, Yoshinobu ; Nakazato, Tomonori ; Kudo, Masumi ; Yashima, Tomoko ; Kondo, Sakiko ; Ikeda, Yasuo ; Okamoto, Shinichiro. / Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. In: Supportive Care in Cancer. 2006 ; Vol. 14, No. 4. pp. 392-395.
@article{b416c9edbbed4e2b9b9c10793f2d3f6c,
title = "Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients",
abstract = "We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis. The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with fludarabine alone or with fludarabine and additional radiation were enrolled in the study. The severity of stomatitis was graded according to the National Cancer Institute - Common Toxicity Criteria. Patients were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). Patients who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8{\%}) of 17 patients receiving 60-min oral cryotherapy and 2 (11.1{\%}) of 18 patients receiving 120-min oral cryotherapy developed grade 2 or 3 stomatitis, respectively. The difference between groups was not statistically significant (P=0.677). The incidence of unpleasant symptoms such as chills and nausea during oral cryotherapy decreased significantly with 60-min oral cryotherapy, as compared with that associated with 120-min oral cryotherapy (P<0.01). These results suggest that 60-min oral cryotherapy is as effective as 120-min oral cryotherapy at preventing high-dose melphalan-induced stomatitis, and shorter treatment might have contributed to relieve patient discomfort during oral cryotherapy.",
keywords = "Hematopoietic stem cell transplantation, High-dose melphalan, Oral cryotherapy, Stomatitis",
author = "Takehiko Mori and Rie Yamazaki and Yoshinobu Aisa and Tomonori Nakazato and Masumi Kudo and Tomoko Yashima and Sakiko Kondo and Yasuo Ikeda and Shinichiro Okamoto",
year = "2006",
month = "4",
doi = "10.1007/s00520-005-0016-3",
language = "English",
volume = "14",
pages = "392--395",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients

AU - Mori, Takehiko

AU - Yamazaki, Rie

AU - Aisa, Yoshinobu

AU - Nakazato, Tomonori

AU - Kudo, Masumi

AU - Yashima, Tomoko

AU - Kondo, Sakiko

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2006/4

Y1 - 2006/4

N2 - We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis. The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with fludarabine alone or with fludarabine and additional radiation were enrolled in the study. The severity of stomatitis was graded according to the National Cancer Institute - Common Toxicity Criteria. Patients were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). Patients who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8%) of 17 patients receiving 60-min oral cryotherapy and 2 (11.1%) of 18 patients receiving 120-min oral cryotherapy developed grade 2 or 3 stomatitis, respectively. The difference between groups was not statistically significant (P=0.677). The incidence of unpleasant symptoms such as chills and nausea during oral cryotherapy decreased significantly with 60-min oral cryotherapy, as compared with that associated with 120-min oral cryotherapy (P<0.01). These results suggest that 60-min oral cryotherapy is as effective as 120-min oral cryotherapy at preventing high-dose melphalan-induced stomatitis, and shorter treatment might have contributed to relieve patient discomfort during oral cryotherapy.

AB - We previously reported the efficacy of oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis. The purpose of this study was to evaluate whether the further shortening of the duration of oral cryotherapy could minimize its side effects while sparing its efficacy. Seventeen consecutive recipients of allogeneic hematopoieic stem cell transplant conditioned with high-dose melphalan in combination with fludarabine alone or with fludarabine and additional radiation were enrolled in the study. The severity of stomatitis was graded according to the National Cancer Institute - Common Toxicity Criteria. Patients were kept on oral cryotherapy shortly before, during, and for additional 30 min after the completion of melphalan administration (60-min oral cryotherapy). Patients who were also enrolled in our previous study received the same type of oral cryotherapy but for additional 90 min after the completion of melphalan administration (120-min oral cryotherapy), and they served as controls. Only 2 (11.8%) of 17 patients receiving 60-min oral cryotherapy and 2 (11.1%) of 18 patients receiving 120-min oral cryotherapy developed grade 2 or 3 stomatitis, respectively. The difference between groups was not statistically significant (P=0.677). The incidence of unpleasant symptoms such as chills and nausea during oral cryotherapy decreased significantly with 60-min oral cryotherapy, as compared with that associated with 120-min oral cryotherapy (P<0.01). These results suggest that 60-min oral cryotherapy is as effective as 120-min oral cryotherapy at preventing high-dose melphalan-induced stomatitis, and shorter treatment might have contributed to relieve patient discomfort during oral cryotherapy.

KW - Hematopoietic stem cell transplantation

KW - High-dose melphalan

KW - Oral cryotherapy

KW - Stomatitis

UR - http://www.scopus.com/inward/record.url?scp=33646433028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646433028&partnerID=8YFLogxK

U2 - 10.1007/s00520-005-0016-3

DO - 10.1007/s00520-005-0016-3

M3 - Article

C2 - 16633843

AN - SCOPUS:33646433028

VL - 14

SP - 392

EP - 395

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 4

ER -